Pharmacology

FDA approves The First Oral Once-Daily Mesalamine For Patients With Active, Mild To Moderate Ulcerative Colitis

By Aleksandr Kavokin in RDoctor
As you probably know ulcerative colitis affects around  half a million Americans. Today in press releases: The U.S. Food and Drug Administration (FDA) has granted approval for LIALDA™ (mesalamine) with MMX® technology for the induction of remission in patients with active, mild to moderate ulcerative colitis. If you do not know much about the disease, here is the information: Ulcerative colitis is a type of inflammatory bowel disease (IBD) that produces inflammation and sores or ulcers along the inside of the large intestine, also called the bowel or colon.

As you probably know ulcerative colitis affects around  half a million Americans.

Today in press releases: The U.S. Food and Drug Administration (FDA) has granted approval for LIALDA™ (mesalamine) with MMX® technology for the induction of remission in patients with active, mild to moderate ulcerative colitis.

If you do not know much about the disease, here is the information:

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that produces inflammation and sores or ulcers along the inside of the large intestine, also called the bowel or colon. The sores can interfere with the normal digestive process, often causing cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements.

Mesalamine and other NSAIDs were often considered as one of the main therapies for autoimmune disorders.

Once daily is easier to remember and to stick to in your daily routine.

Categories
Pharmacology
Profile picture for user rdoctor

Aleksandr Kavokin, MD, PhD. Aleksandr received his MD from Russian State Medical University, then did his PhD in Immunology and Allergy. Later he did a year of research in Cancer Biology at Medical University of South Carolina, 5 years of research in Cardiology at Yale University School of Medicine. He also had training in General Surgery at Graduate Hospital in Philadelphia. Oleg Kavokin, MD. Oleg received his MD from Russian State Medical University with specialization in Medical Cybernetics. He wrote numerous software programs for on-line and off-line management. Alexey Kavokin, PhD… Read more

Recent posts by this author:

Measles Deaths Fall By 60 Percent Globally

FDA approves The First Oral Once-Daily Mesalamine For Patients With Active, Mild To Moderate Ulcerative Colitis

More posts by Aleksandr Kavokin